More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B....

More on Johnson & Johnson (JNJ): Pharmaceutical sales in the U.S. rose 14.6% Y/Y to $3.288B. On a regional basis, gains in the Western Hemisphere and Asia-Pacific Africa helped to offset a 3.4% decline of revenue in Europe. Sees full-year 2012 EPS of $5.05-$5.10, lower than prior guidance of $5.00-$5.07 and the consensus mark of analysts calling for $5.06. Shares +1.2% premarket. (PR)

From other sites
Comments (4)
  • Larry Smith
    , contributor
    Comments (3124) | Send Message
    I think the guidance would be higher
    16 Oct 2012, 08:02 AM Reply Like
  • BlueOkie
    , contributor
    Comments (9188) | Send Message
    Nice increases considering we cannot get anything from Congress or President on direction. The fiscal cliff is coming, I'm surprised things are this good. VOTE
    16 Oct 2012, 08:07 AM Reply Like
  • tomlos
    , contributor
    Comments (1278) | Send Message
    Agreed. JNJ continues to deliver, even when analysts are rating them a sell. What a joke.
    16 Oct 2012, 08:12 AM Reply Like
  • Old Trader
    , contributor
    Comments (5732) | Send Message
    Fwiw, M* still considers JNJ as "undervalued", pointing to a strong pipeline of new drugs more than offsetting weak performance in their consumer segment.
    16 Oct 2012, 08:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs